<p>Sentinel Trust Co. LBA 在第三季度購買了瑞士羅氏控股公司（OTCMKTS:RHHBY - 免費報告）的新股份，根據該公司在最近向證券交易委員會（SEC）的披露。該基金購買了 21,507 股公司股票，價值約為 878,000 美元。</p>
<ul>
<li>3 只投資超過 1000 億美元的大型製藥股。</li>
</ul>
<p>其他幾家機構投資者和對沖基金也對該股票的持倉進行了調整。Oakworth Capital Inc. 在第三季度以約 57,000 美元的價格收購了羅氏的新股份。First Horizon Advisors Inc. 在第二季度將其在羅氏的股份增加了 81.2%。First Horizon Advisors Inc. 現在擁有 1,843 股公司股票，價值 75,000 美元，此前在上個季度又購買了 826 股。Salomon &amp; Ludwin LLC 在第三季度將其在羅氏的持股增加了 256.6%。Salomon &amp; Ludwin LLC 現在擁有 2,853 股公司股票，價值 129,000 美元，此前在上個季度又購買了 2,053 股。Enterprise Financial Services Corp 在第二季度以 208,000 美元的價格收購了羅氏的新股份。最後，FineMark National Bank &amp; Trust 在第二季度以約 210,000 美元的價格收購了羅氏的新股份。</p>
<h2>羅氏公司新聞要點</h2>
<p>以下是本週影響羅氏的主要新聞：</p>
<ul>
<li>積極情緒：羅氏報告了強勁的 2025 年業績——銷售增長 7%——並預計 2026 年將實現中個位數的銷售增長和高個位數的核心每股收益增長；管理層還計劃提高股息，以支持長期股東價值。臨時公告：羅氏報告 2025 年業績強勁，銷售增長 7%。</li>
<li>積極情緒：羅氏的產品管線——尤其是肥胖和心血管項目——被認為是潛在的增長驅動因素，並在 GLP-1 市場中構成了可信的競爭者，支撐了長期上漲的 “買入” 論點。羅氏的全年收益：穩健，無警報——肥胖承諾使買入論點成立。</li>
<li>中性情緒：收益基本符合預期，未能激發市場熱情，導致股票在投資者等待更清晰的產品管線變現證據時保持區間波動。製藥公司羅氏和賽諾菲談論其產品管線，但收益未能激發市場熱情。</li>
<li>中性情緒：高盛對羅氏（RHHVF/RHHBY）給予 “持有” 評級，反映出中立觀點，可能限制了儘管前景樂觀但仍然有限的買入興趣。羅氏控股公司（RHHVF）獲得高盛的持有評級。</li>
<li>消極情緒：貨幣（外匯）逆風對報告結果產生了重大影響，降低了基礎增長的表面影響，並造成了短期收益的不確定性，給股票帶來了壓力。羅氏的年度業績受到貨幣逆風的影響。</li>
</ul>
<h2>羅氏股票表現</h2>
<ul>
<li>Viking Therapeutics：GLP-1 製造商會在批准前被收購嗎？</li>
</ul>
<p>RHHBY 的股票在週五開盤價為 56.75 美元。該公司的債務與股本比率為 0.80，速動比率為 1.02，流動比率為 1.29。羅氏控股公司的 12 個月低點為 34.75 美元，12 個月高點為 57.29 美元。該公司的 50 日簡單移動平均線為 51.76 美元，200 日簡單移動平均線為 45.39 美元。</p>
<h2>華爾街分析師觀點</h2>
<p>幾位股票研究分析師最近對該公司發表了看法。巴克萊在 1 月 6 日的研究報告中將羅氏的評級從 “持平” 上調至 “增持”。花旗在週二的研究報告中開始覆蓋羅氏，並對該公司給予 “買入” 評級。德意志銀行在 11 月 11 日的研究報告中將羅氏的評級從 “賣出” 上調至 “持有”。摩根士丹利在 12 月 2 日的研究報告中重申了對羅氏股票的 “減持” 評級。最後，高盛在 1 月 15 日的報告中將羅氏的評級從 “賣出” 上調至 “持有”。兩位股票研究分析師對該股票給予了強烈買入評級，三位給予了買入評級，四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，羅氏的共識評級為 “適度買入”，共識目標價為 57.00 美元。</p>
<ul>
<li>NVIDIA 投資了這兩隻人工智能股票，你應該投資嗎？</li>
</ul>
<p><strong>獲取我們對羅氏的最新分析</strong></p>
<h2>羅氏公司簡介</h2>
<p>（免費報告）</p>
<p>羅氏控股公司是一家總部位於巴塞爾的瑞士跨國醫療保健公司，成立於 1896 年，由弗裏茨·霍夫曼 - 拉·羅氏創立。該公司主要通過兩個互補的部門運營——製藥和診斷，並以將藥物開發與診斷能力相結合以推動個性化醫療而聞名。在美國和其他國際市場，股票以美國存託憑證的形式交易，代碼為 RHHBY OTCMKTS: RHHBY。</p>
<p>在製藥領域，羅氏專注於開發和商業化處方藥，涵蓋包括腫瘤學、免疫學、傳染病和神經科學等治療領域，特別強調靶向生物製劑和個性化療法。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過羅氏</li>
<li>股票市場傳奇警告：“市場即將迎來不祥的一天……”</li>
<li>你需要擁有黃金的另一個理由… [即將耗盡]</li>
<li>特朗普的最後震驚行動將於 2 月 24 日開始</li>
<li>新消息：黃金創歷史新高</li>
<li>德意志銀行剛剛將其黃金目標上調至 6,000 美元</li>
</ul>
<p><strong>想看看其他對沖基金持有的 RHHBY 嗎？</strong> 訪問 HoldingsChannel.com，獲取羅氏控股公司（OTCMKTS:RHHBY - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在羅氏嗎？</h2>
<p>在考慮羅氏之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而羅氏並不在名單上。</p>
<p>雖然羅氏目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Sentinel Trust Co. LBA 在第三季度收購了 21,507 股羅氏控股公司（OTCMKTS:RHHBY），價值約 878,000 美元，已向美國證券交易委員會（SEC）披露。其他機構投資者也調整了在羅氏的持倉。該公司報告了強勁的 2025 年業績，銷售增長達到 7%，並計劃提高股息。然而，匯率波動對收益產生了影響，導致分析師的情緒趨於中性，高盛給予了 “持有” 評級。羅氏的股票共識評級為 “適度買入”，目標價格為 57.00 美元</p>

<p>Sentinel Trust Co. LBA purchased a new stake in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 21,507 shares of the company's stock, valued at approximately $878,000.</p>
<div class="lb-trans"><p>Sentinel Trust Co. LBA 在第三季度購買了瑞士羅氏控股公司（OTCMKTS:RHHBY - 免費報告）的新股份，根據該公司在最近向證券交易委員會（SEC）的披露。該基金購買了 21,507 股公司股票，價值約為 878,000 美元。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只投資超過 1000 億美元的大型製藥股。</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also made changes to their positions in the stock. Oakworth Capital Inc. acquired a new stake in Roche in the 3rd quarter valued at about $57,000. First Horizon Advisors Inc. increased its stake in shares of Roche by 81.2% in the second quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company's stock worth $75,000 after acquiring an additional 826 shares during the last quarter. Salomon &amp; Ludwin LLC increased its holdings in Roche by 256.6% in the third quarter. Salomon &amp; Ludwin LLC now owns 2,853 shares of the company's stock worth $129,000 after buying an additional 2,053 shares during the last quarter. Enterprise Financial Services Corp acquired a new position in Roche during the second quarter worth $208,000. Finally, FineMark National Bank &amp; Trust acquired a new position in Roche during the second quarter valued at approximately $210,000.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金也對該股票的持倉進行了調整。Oakworth Capital Inc. 在第三季度以約 57,000 美元的價格收購了羅氏的新股份。First Horizon Advisors Inc. 在第二季度將其在羅氏的股份增加了 81.2%。First Horizon Advisors Inc. 現在擁有 1,843 股公司股票，價值 75,000 美元，此前在上個季度又購買了 826 股。Salomon &amp; Ludwin LLC 在第三季度將其在羅氏的持股增加了 256.6%。Salomon &amp; Ludwin LLC 現在擁有 2,853 股公司股票，價值 129,000 美元，此前在上個季度又購買了 2,053 股。Enterprise Financial Services Corp 在第二季度以 208,000 美元的價格收購了羅氏的新股份。最後，FineMark National Bank &amp; Trust 在第二季度以約 210,000 美元的價格收購了羅氏的新股份。</p>
</div><h2>Key Roche News</h2>
<div class="lb-trans"><h2>羅氏公司新聞要點</h2>
</div><p>Here are the key news stories impacting Roche this week:</p>
<div class="lb-trans"><p>以下是本週影響羅氏的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Roche reported strong 2025 results — 7% sales growth — and guided to mid-single-digit sales growth and high-single-digit core EPS growth for 2026; management also plans to raise the dividend, supporting longer-term shareholder value. Ad-hoc announcement: Roche reports strong 2025 results with 7% sales growth</li>
<li>Positive Sentiment: Roche’s pipeline — especially obesity and cardiovascular programs — is highlighted as a potential growth driver and a credible challenger in the GLP‑1 market, underpinning the “buy” thesis for longer-term upside. Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case</li>
<li>Neutral Sentiment: Earnings essentially matched expectations and failed to excite the market, leaving the stock rangebound as investors await clearer proof of pipeline monetization. Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite</li>
<li>Neutral Sentiment: Goldman Sachs assigned a “Hold” to Roche (RHHVF/RHHBY), reflecting a neutral view that likely limited buying interest despite the upbeat guidance. Roche Holding AG (RHHVF) Gets a Hold from Goldman Sachs</li>
<li>Negative Sentiment: Currency (FX) headwinds materially weighed on reported results, reducing the headline impact of underlying growth and creating near-term earnings uncertainty that pressured the stock. Roche's annual results hit by currency headwinds</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：羅氏報告了強勁的 2025 年業績——銷售增長 7%——並預計 2026 年將實現中個位數的銷售增長和高個位數的核心每股收益增長；管理層還計劃提高股息，以支持長期股東價值。臨時公告：羅氏報告 2025 年業績強勁，銷售增長 7%。</li>
<li>積極情緒：羅氏的產品管線——尤其是肥胖和心血管項目——被認為是潛在的增長驅動因素，並在 GLP-1 市場中構成了可信的競爭者，支撐了長期上漲的 “買入” 論點。羅氏的全年收益：穩健，無警報——肥胖承諾使買入論點成立。</li>
<li>中性情緒：收益基本符合預期，未能激發市場熱情，導致股票在投資者等待更清晰的產品管線變現證據時保持區間波動。製藥公司羅氏和賽諾菲談論其產品管線，但收益未能激發市場熱情。</li>
<li>中性情緒：高盛對羅氏（RHHVF/RHHBY）給予 “持有” 評級，反映出中立觀點，可能限制了儘管前景樂觀但仍然有限的買入興趣。羅氏控股公司（RHHVF）獲得高盛的持有評級。</li>
<li>消極情緒：貨幣（外匯）逆風對報告結果產生了重大影響，降低了基礎增長的表面影響，並造成了短期收益的不確定性，給股票帶來了壓力。羅氏的年度業績受到貨幣逆風的影響。</li>
</ul>
</div><h2>Roche Stock Performance</h2>
<div class="lb-trans"><h2>羅氏股票表現</h2>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics：GLP-1 製造商會在批准前被收購嗎？</li>
</ul>
</div><p>Shares of RHHBY opened at $56.75 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.02 and a current ratio of 1.29. Roche Holding AG has a 12 month low of $34.75 and a 12 month high of $57.29. The firm has a fifty day simple moving average of $51.76 and a 200 day simple moving average of $45.39.</p>
<div class="lb-trans"><p>RHHBY 的股票在週五開盤價為 56.75 美元。該公司的債務與股本比率為 0.80，速動比率為 1.02，流動比率為 1.29。羅氏控股公司的 12 個月低點為 34.75 美元，12 個月高點為 57.29 美元。該公司的 50 日簡單移動平均線為 51.76 美元，200 日簡單移動平均線為 45.39 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several equities research analysts have recently weighed in on the company. Barclays raised Roche from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating in a research report on Tuesday, January 6th. Citigroup initiated coverage on Roche in a research report on Tuesday. They issued a &#34;buy&#34; rating for the company. Deutsche Bank Aktiengesellschaft upgraded Roche from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, November 11th. Morgan Stanley reaffirmed an &#34;underweight&#34; rating on shares of Roche in a research note on Tuesday, December 2nd. Finally, The Goldman Sachs Group upgraded Roche from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Thursday, January 15th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Roche has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $57.00.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該公司發表了看法。巴克萊在 1 月 6 日的研究報告中將羅氏的評級從 “持平” 上調至 “增持”。花旗在週二的研究報告中開始覆蓋羅氏，並對該公司給予 “買入” 評級。德意志銀行在 11 月 11 日的研究報告中將羅氏的評級從 “賣出” 上調至 “持有”。摩根士丹利在 12 月 2 日的研究報告中重申了對羅氏股票的 “減持” 評級。最後，高盛在 1 月 15 日的報告中將羅氏的評級從 “賣出” 上調至 “持有”。兩位股票研究分析師對該股票給予了強烈買入評級，三位給予了買入評級，四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，羅氏的共識評級為 “適度買入”，共識目標價為 57.00 美元。</p>
</div><ul>
<li>NVIDIA Invested in These 2 AI Stocks, Should You?</li>
</ul>
<div class="lb-trans"><ul>
<li>NVIDIA 投資了這兩隻人工智能股票，你應該投資嗎？</li>
</ul>
</div><p><strong>Get Our Latest Analysis on Roche</strong></p>
<div class="lb-trans"><p><strong>獲取我們對羅氏的最新分析</strong></p>
</div><h2>Roche Company Profile</h2>
<div class="lb-trans"><h2>羅氏公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.</p>
<div class="lb-trans"><p>羅氏控股公司是一家總部位於巴塞爾的瑞士跨國醫療保健公司，成立於 1896 年，由弗裏茨·霍夫曼 - 拉·羅氏創立。該公司主要通過兩個互補的部門運營——製藥和診斷，並以將藥物開發與診斷能力相結合以推動個性化醫療而聞名。在美國和其他國際市場，股票以美國存託憑證的形式交易，代碼為 RHHBY OTCMKTS: RHHBY。</p>
</div><p>In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.</p>
<div class="lb-trans"><p>在製藥領域，羅氏專注於開發和商業化處方藥，涵蓋包括腫瘤學、免疫學、傳染病和神經科學等治療領域，特別強調靶向生物製劑和個性化療法。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Roche</li>
<li>Stock market legend warns: “An Ominous Day Is Coming for the Markets…”</li>
<li>Another reason you need to own gold… [running out]</li>
<li>Trump’s Final Shocking Act Begins February 24</li>
<li>NEW: Gold makes history</li>
<li>Deutsche Bank Just Raised Their Gold Target to $6,000</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過羅氏</li>
<li>股票市場傳奇警告：“市場即將迎來不祥的一天……”</li>
<li>你需要擁有黃金的另一個理由… [即將耗盡]</li>
<li>特朗普的最後震驚行動將於 2 月 24 日開始</li>
<li>新消息：黃金創歷史新高</li>
<li>德意志銀行剛剛將其黃金目標上調至 6,000 美元</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding RHHBY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 RHHBY 嗎？</strong> 訪問 HoldingsChannel.com，獲取羅氏控股公司（OTCMKTS:RHHBY - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=OTCMKTS&amp;Symbol=RHHBY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Roche Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在羅氏嗎？</h2>
</div><p>Before you consider Roche, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮羅氏之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而羅氏並不在名單上。</p>
</div><p>While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然羅氏目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Sentinel Trust Co. LBA Buys Shares of 21,507 Roche Holding AG $RHHBY

Market Beat

2 倍做多納斯達克生物技術 ETF - ProShares

美國制藥 ETF - iShares

ROCHE HOLDINGS AG

醫藥突破 ETF - ALPS

醫療業 ETF - SPDR

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

動態生物技術與基因組 ETF - Invesco

醫療業 ETF - Vanguard

羅氏(ADR)

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

Sentinel Trust Co. LBA 購買了 21,507 股羅氏 (ADR) 的股票$RHHBY